HELX stock forecast, quote, news & analysis

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Guardant Health (NASDAQ:GH).

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 40.37B. The market cap for tickers in the group ranges from 308.09M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is VYGR at 308.09M.

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was -9%. For the same ETF, the average monthly price growth was -11%, and the average quarterly price growth was -10%. NTRA experienced the highest price growth at 9%, while PACB experienced the biggest fall at -31%.

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was 32%. For the same stocks of the ETF, the average monthly volume growth was 150% and the average quarterly volume growth was 104%